Program Enrichment

David Soto-Pantoja, PhD, investigates cell surface receptor CD47 as an immunotherapy for breast, lung, head and neck cancers and melanoma. Through clinical trials and animal model collaborations, he explores the effects of CD47 targeting on tumor cell bioenergetics, with the goal of developing anti-cancer therapeutics that inhibit tumor growth and prevent chemotherapy-related cardiac toxicity.